|
1
|
Martínez-Bosch N and Navarro P: Galectins
in the tumor microenvironment: Focus on galectin-1. Adv Exp Med
Biol. 1259:17–38. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Elola MT, Chiesa ME, Alberti AF, Mordoh J
and Fink NE: Galectin-1 receptors in different cell types. J Biomed
Sci. 12:13–29. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chung LY, Tang SJ, Sun GH, Chou TY, Yeh
TS, Yu SL and Sun KH: Galectin-1 promotes lung cancer progression
and chemoresistance by upregulating p38 MAPK, ERK, and
cyclooxygenase-2. Clin Cancer Res. 18:4037–4047. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Holst JM, Ludvigsen M, Hamilton-Dutoit SJ,
Bendix K, Plesner TL, Nørgaard P, Møller MB, Steiniche T,
Rabinovich GA, d'Amore F and Pedersen MB: High intra-tumoural
galectin-1 expression predicts adverse outcome in ALK-
ALCL and CD30+ PTCL-NOS. Hematol Oncol. 38:59–66.
2020.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Verschuere T, Toelen J, Maes W, Poirier F,
Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, et
al: Glioma-derived galectin-1 regulates innate and adaptive
antitumor immunity. Int J Cancer. 134:873–884. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gajiwala S, Torgeson A, Garrido-Laguna I,
Kinsey C and Lloyd S: Combination immunotherapy and radiation
therapy strategies for pancreatic cancer-targeting multiple steps
in the cancer immunity cycle. J Gastrointest Oncol. 9:1014–1026.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Petrovic S, Radosavljevic GD, Pantic J,
Jovanovic I, Jankovic N and Arsenijevic N: Circulating and tissue
galectin-1 and galectin-3 in colorectal carcinoma: Association with
clinicopathological parameters, serum CEA, IL-17 and IL23. J BUON.
21:941–949. 2016.PubMed/NCBI
|
|
9
|
Chen L, Yao Y, Sun L, Zhou J, Liu J, Wang
J, Li J and Tang J: Clinical implication of the serum galectin-1
expression in epithelial ovarian cancer patients. J Ovarian Res.
8(78)2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen K, Cai Y, Zhang M, Wu Z and Wu Y:
Both serum and tissue galectin-1 levels are associated with adverse
clinical features in neuroblastoma. Pediatr Blood Cancer.
65(e27229)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gurel Cayir E, Demir L, Varol U, Atahan
MK, Salman T, Oflazoglu U, Yildiz Y, Taskaynatan H, Saray S,
Kucukzeybek Y, et al: Preliminary study of serum galectin-1 in
breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]. J
BUON. 25:675–680. 2020.PubMed/NCBI
|
|
12
|
Wu KL, Chen HH, Pen CT, Yeh WL, Huang EY,
Hsiao CC and Yang KD: Circulating galectin-1 and 90K/Mac-2BP
correlated with the tumor stages of patients with colorectal
cancer. Biomed Res Int. 2015(306964)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shimada H, Ochiai T and Nomura F: Japan
p53 Antibody Research Group. Titration of serum p53 antibodies in
1,085 patients with various types of malignant tumors: A
multi-institutional analysis by the Japan p53 antibody research
group. Cancer. 97:682–689. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shimada H, Takeda A, Arima M, Okazumi S,
Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et
al: Serum p53 antibody is a useful tumor marker in superficial
esophageal squamous cell carcinoma. Cancer. 89:1677–1683.
2000.PubMed/NCBI
|
|
15
|
Oshima Y, Shimada H, Yajima S, Nanami T,
Matsushita K, Nomura F, Kainuma O, Takiguchi N, Soda H, Ueda T, et
al: NY-ESO-1 autoantibody as a tumor-specific biomarker for
esophageal cancer: Screening in 1969 patients with various cancers.
J Gastroenterol. 51:30–34. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shiratori F, Shimada H, Nagata M, Kubota
Y, Otsuka Y and Kaneko H: Serum galectin-1 autoantibodies in
patients with hepatocellular carcinoma. Toho J Med. 2:67–72.
2016.
|
|
17
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ushigome M, Shimada H, Miura Y, Yoshida K,
Kaneko T, Koda T, Nagashima Y, Suzuki T, Kagami S and Funahashi K:
Changing pattern of tumor markers in recurrent colorectal cancer
patients before surgery to recurrence: Serum p53 antibodies, CA19-9
and CEA. Int J Clin Oncol. 25:622–632. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the task force
of the Japanese gastric cancer association. Gastric Cancer.
17:26–33. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sengupta S and Parikh ND: Biomarker
development for hepatocellular carcinoma early detection: Current
and future perspectives. Hepat Oncol. 4:111–122. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nakamura H and Nishimura T: History,
molecular features, and clinical importance of conventional serum
biomarkers in lung cancer. Surg Today. 47:1037–1059.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai MH,
Freg WC and Chow LP: Integrated stable isotope labeling by
aminoacids in cell culture (SILAC) and isobaric tags for relative
and absolute quantitation (iTRAQ) quantitative proteomic analysis
identifies galectin-1 as a potential biomarker for predicting
sorafenib resistance in liver cancer. Mol Cell Proteomics.
14:1527–1545. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Carlini MJ, Roitman P, Nuñez M, Pallotta
MG, Boggio G, Smith D, Salatino M, Joffé ED, Rabinovich GA and
Puricelli LI: Clinical relevance of galectin-1 expression in
non-small cell lung cancer patients. Lung Cancer. 84:73–78.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nagy N, Legendre H, Engels O, André S,
Kaltner H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ,
et al: Refined prognostic evaluation in colon carcinoma using
immunohistochemical galectin fingerprinting. Cancer. 97:1849–1858.
2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
He XJ, Tao HQ, Hu ZM, Ma YY, Xu J, Wang
HJ, Xia YJ, Li l, Fei BY, Li YQ and Chen JZ: Expression of
galectin-1 in carcinoma-associated fibroblasts promotes gastric
cancer cell invasion through upregulation of integrin β1. Cancer
Sci. 105:1402–1410. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Okada R, Otsuka Y, Wakabayashi T, Shinoda
M, Aoki T, Murakami M, Arizumi S, Yamamoto M, Aramaki O, Takayama
T, et al: Six autoantibodies as potential serum biomarkers of
hepatocellular carcinoma: A prospective multicenter study. Int J
Cancer. 47:2578–2586. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Takashi S, Satoshi Y, Akihiko O, Naoya Y,
Yusuke T, Kentaro M, Yu O, Yasuaki N, Koichi Y, Takashi F, et al:
Clinical impact of preoperative serum p53 antibody titers in 1,487
patients with surgically treated esophageal squamous cell
carcinoma: A multi-institutional study. Esophagus. 18:65–71.
2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shimada H, Nagata M, Nabeya Y, Yajima S,
Oshima Y and Itami M: Paradoxical changing of serum p53 antibody
titers during chemotherapy for a stage IV esophageal squamous cell
carcinoma. Int Cancer Conf J. 3:232–236. 2014.
|
|
29
|
Van Woensel M, Mathivet T, Wauthoz N,
Rosière R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon
L, et al: Sensitization of glioblastoma tumor micro-environment to
chemo- and immunotherapy by galectin-1 intranasal knock-down
strategy. Sci Rep. 7(1217)2017.PubMed/NCBI View Article : Google Scholar
|
